See more : Celyad Oncology SA (CYAD.BR) Income Statement Analysis – Financial Results
Complete financial analysis of Aurisco Pharmaceutical Co.,Ltd. (605116.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aurisco Pharmaceutical Co.,Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Nihon Seimitsu Co., Ltd. (7771.T) Income Statement Analysis – Financial Results
- Fujian Furi Electronics Co.,Ltd (600203.SS) Income Statement Analysis – Financial Results
- Zhejiang Longsheng Group Co.,Ltd (600352.SS) Income Statement Analysis – Financial Results
- The NAGA Group AG (NAGGF) Income Statement Analysis – Financial Results
- Shurgard Self Storage S.A. (SSSAF) Income Statement Analysis – Financial Results
Aurisco Pharmaceutical Co.,Ltd. (605116.SS)
About Aurisco Pharmaceutical Co.,Ltd.
Aurisco Pharmaceutical Co.,Ltd. engages in research, manufacturing, and marketing of intermediates, specialty active pharmaceutical ingredients (API's), and formulations catering to the pharmaceutical market worldwide. The company offers steroids, oncology, antiretroviral, and other APIs and intermediates. It also provides contract manufacturing services and related development works for chemicals, intermediates, and API's. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.26B | 1.01B | 803.36M | 721.44M | 581.63M | 575.41M | 544.40M | 590.42M |
| Cost of Revenue | 556.56M | 487.68M | 408.64M | 380.54M | 283.27M | 304.62M | 280.26M | 285.39M |
| Gross Profit | 705.97M | 520.40M | 394.72M | 340.90M | 298.36M | 270.79M | 264.15M | 305.03M |
| Gross Profit Ratio | 55.92% | 51.62% | 49.13% | 47.25% | 51.30% | 47.06% | 48.52% | 51.66% |
| Research & Development | 136.89M | 117.26M | 69.35M | 47.35M | 35.10M | 24.65M | 23.53M | 17.90M |
| General & Administrative | 71.23M | 50.19M | 41.35M | 24.57M | 20.84M | 16.26M | 96.72M | 157.09M |
| Selling & Marketing | 75.95M | 39.86M | 29.70M | 21.35M | 30.24M | 28.35M | 22.27M | 31.11M |
| SG&A | 147.18M | 90.05M | 71.05M | 45.92M | 51.08M | 44.61M | 118.99M | 188.20M |
| Other Expenses | 91.18M | 84.74M | 62.04M | 48.86M | 42.85M | -476.33K | -31.46K | 1.49M |
| Operating Expenses | 375.25M | 292.05M | 202.44M | 142.13M | 129.03M | 109.38M | 180.20M | 212.65M |
| Cost & Expenses | 931.80M | 779.72M | 611.08M | 522.67M | 412.30M | 414.01M | 460.46M | 498.04M |
| Interest Income | 16.53M | 4.41M | 8.27M | 5.46M | 2.08M | 1.08M | 370.56K | 0.00 |
| Interest Expense | 3.65M | 1.01M | 643.75K | 529.62K | 545.96K | 3.05K | 1.54M | 0.00 |
| Depreciation & Amortization | 81.65M | 70.80M | 54.77M | 32.02M | 27.90M | 7.16M | 5.97M | 6.06M |
| EBITDA | 414.38M | 313.21M | 247.43M | 223.90M | 234.76M | 161.31M | 88.17M | 101.26M |
| EBITDA Ratio | 32.82% | 32.19% | 30.67% | 32.21% | 34.39% | 32.52% | 16.74% | 14.99% |
| Operating Income | 330.73M | 241.28M | 193.62M | 187.27M | 170.71M | 164.66M | 70.05M | 111.79M |
| Operating Income Ratio | 26.20% | 23.93% | 24.10% | 25.96% | 29.35% | 28.62% | 12.87% | 18.93% |
| Total Other Income/Expenses | -1.65M | -524.73K | -1.61M | -1.53M | 35.60M | -476.33K | -31.46K | 1.49M |
| Income Before Tax | 329.08M | 240.75M | 192.01M | 185.74M | 206.31M | 164.18M | 70.02M | 113.28M |
| Income Before Tax Ratio | 26.07% | 23.88% | 23.90% | 25.75% | 35.47% | 28.53% | 12.86% | 19.19% |
| Income Tax Expense | 40.01M | 32.54M | 23.73M | 28.51M | 20.18M | 27.35M | 25.55M | 31.45M |
| Net Income | 289.42M | 210.96M | 168.71M | 157.23M | 186.13M | 136.83M | 44.72M | 86.70M |
| Net Income Ratio | 22.92% | 20.93% | 21.00% | 21.79% | 32.00% | 23.78% | 8.21% | 14.69% |
| EPS | 0.71 | 0.53 | 0.42 | 0.39 | 0.46 | 0.38 | 0.12 | 0.23 |
| EPS Diluted | 0.71 | 0.53 | 0.42 | 0.39 | 0.46 | 0.38 | 0.12 | 0.23 |
| Weighted Avg Shares Out | 407.63M | 401.00M | 401.00M | 401.00M | 401.00M | 360.08M | 372.67M | 372.67M |
| Weighted Avg Shares Out (Dil) | 407.63M | 401.00M | 401.00M | 401.00M | 401.00M | 360.08M | 372.67M | 372.67M |
Source: https://incomestatements.info
Category: Stock Reports